MicroRNAs and Their Role in Breast Cancer Metabolism (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2024 Dec 5

PMID 39635852

Authors

Wen Xuan Lee

Bann Siang Yeo

Rozi Mahmud

Geok Chin Tan

Mohamed Ibrahim Abdul Wahid

Yoke Kqueen Cheah

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) continues to be the leading cause of cancer‑related mortality among women, placing a substantial disease burden on the global female population. MicroRNAs (miRNAs) are members of a large class of non‑coding RNAs capable of regulating gene expression at the post‑transcriptional level. With cases of early‑onset BC on the rise, miRNAs are promising biomarkers and therapeutic targets for early BC detection and treatment. Dysregulated miRNA expression is known to be closely linked to BC development and metastasis in cancer cells via metabolic reprogramming. Normal cellular metabolism is tightly regulated by various complex signaling pathways. Therefore, dysregulation of metabolism due to metabolic reprogramming is considered a hallmark of cancer. The present review delves into the crucial roles that miRNAs serve in disordered cellular metabolism of BC by targeting gene transcripts, key metabolic enzymes and transporter proteins responsible for regulating major cellular metabolism pathways. The future outlook and clinical implications of miRNAs as potential diagnostic, prognostic and therapeutic markers in BC metabolism are also discussed.

Citing Articles

MicroRNA Gets a Mighty Award.

Li Y, Chen S, Rao H, Cui S, Chen G Adv Sci (Weinh). 2025; 12(7):e2414625.

PMID: 39836690 PMC: 11831481. DOI: 10.1002/advs.202414625.

References

Du Y, Wei N, Ma R, Jiang S, Song D . A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer. Cell Death Dis. 2020; 11(9):731. PMC: 7481213. DOI: 10.1038/s41419-020-02952-6. View

Yang M, Zhang Y, Li M, Liu X, Darvishi M . The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies. Cancer Cell Int. 2023; 23(1):24. PMC: 9912632. DOI: 10.1186/s12935-022-02837-y. View

Wang L, Zhang S, Wang X . The Metabolic Mechanisms of Breast Cancer Metastasis. Front Oncol. 2021; 10:602416. PMC: 7817624. DOI: 10.3389/fonc.2020.602416. View

Park J, Coffey N, Limoges A, Le A . The Heterogeneity of Lipid Metabolism in Cancer. Adv Exp Med Biol. 2018; 1063:33-55. DOI: 10.1007/978-3-319-77736-8_3. View

Vona R, Iessi E, Matarrese P . Role of Cholesterol and Lipid Rafts in Cancer Signaling: A Promising Therapeutic Opportunity?. Front Cell Dev Biol. 2021; 9:622908. PMC: 8017202. DOI: 10.3389/fcell.2021.622908. View

Kurmi K, Haigis M . Nitrogen Metabolism in Cancer and Immunity. Trends Cell Biol. 2020; 30(5):408-424. PMC: 7386658. DOI: 10.1016/j.tcb.2020.02.005. View

Budczies J, Pfitzner B, Gyorffy B, Winzer K, Radke C, Dietel M . Glutamate enrichment as new diagnostic opportunity in breast cancer. Int J Cancer. 2014; 136(7):1619-28. DOI: 10.1002/ijc.29152. View

Chan B, Manley J, Lee J, Singh S . The emerging roles of microRNAs in cancer metabolism. Cancer Lett. 2014; 356(2 Pt A):301–8. DOI: 10.1016/j.canlet.2014.10.011. View

Schormann N, Hayden K, Lee P, Banerjee S, Chattopadhyay D . An overview of structure, function, and regulation of pyruvate kinases. Protein Sci. 2019; 28(10):1771-1784. PMC: 6739817. DOI: 10.1002/pro.3691. View

10.

Fan S, Shahid M, Jin P, Asher A, Kim J . Identification of Metabolic Alterations in Breast Cancer Using Mass Spectrometry-Based Metabolomic Analysis. Metabolites. 2020; 10(4). PMC: 7241246. DOI: 10.3390/metabo10040170. View

11.

Saito Y, Soga T . Amino acid transporters as emerging therapeutic targets in cancer. Cancer Sci. 2021; 112(8):2958-2965. PMC: 8353895. DOI: 10.1111/cas.15006. View

12.

Xiao X, Huang X, Ye F, Chen B, Song C, Wen J . The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Sci Rep. 2016; 6:21735. PMC: 4763192. DOI: 10.1038/srep21735. View

13.

Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D . Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One. 2011; 5(12):e15573. PMC: 3013113. DOI: 10.1371/journal.pone.0015573. View

14.

Garrido-Palacios A, Rojas Carvajal A, Nunez-Negrillo A, Cortes-Martin J, Sanchez-Garcia J, Aguilar-Cordero M . MicroRNA Dysregulation in Early Breast Cancer Diagnosis: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2023; 24(9). PMC: 10179484. DOI: 10.3390/ijms24098270. View

15.

van Geldermalsen M, Wang Q, Nagarajah R, Marshall A, Thoeng A, Gao D . ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2015; 35(24):3201-8. PMC: 4914826. DOI: 10.1038/onc.2015.381. View

16.

Amiri-Dashatan N, Farrokhi Yekta R, Koushki M, Arefi Oskouie A, Esfahani H, Taheri S . Metabolomic study of serum in patients with invasive ductal breast carcinoma with LC-MS/MS approach. Int J Biol Markers. 2022; 37(4):349-359. DOI: 10.1177/03936155221123343. View

17.

Fogazzi V, Kapahnke M, Cataldo A, Plantamura I, Tagliabue E, Di Cosimo S . The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective. Cancers (Basel). 2022; 14(21). PMC: 9657949. DOI: 10.3390/cancers14215326. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Budczies J, Brockmoller S, Muller B, Barupal D, Richter-Ehrenstein C, Kleine-Tebbe A . Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J Proteomics. 2013; 94:279-88. DOI: 10.1016/j.jprot.2013.10.002. View

20.

Lee M, Azmiyaty Amar Ma Ruf C, Nadhirah Izhar D, Nafisah Ishak S, Wan Jamaluddin W, Yaacob S . Awareness on breast cancer screening in Malaysia: a cross sectional study. Biomedicine (Taipei). 2019; 9(3):18. PMC: 6711317. DOI: 10.1051/bmdcn/2019090318. View